Bristol Myers Squibb (CELG-RI) Common Equity (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has 18 years of Common Equity data on file, last reported at $20.1 billion in Q1 2026.

• Common Equity for Q1 2026 came in at $20.1 billion, up 24.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.1 billion (up 24.81% YoY), and the FY2025 annual result was $18.5 billion, up 24.1% from the prior year.
• Common Equity grew to $20.1 billion in Q1 2026 per CELG-RI's latest filing, from $18.5 billion in the prior quarter.
• Over five years, Common Equity peaked at $46.1 billion in Q2 2025 and troughed at -$43.7 billion in Q2 2024.
• A 5-year average of $15.1 billion and a median of $16.1 billion in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2024: Common Equity jumped 80047.37% in 2023, then tumbled 196.45% in 2024.
• A 5-year view of Common Equity shows it stood at $57.0 million in 2022, then jumped by 80047.37% to $45.7 billion in 2023, then sank by 67.36% to $14.9 billion in 2024, then increased by 24.1% to $18.5 billion in 2025, then advanced by 8.62% to $20.1 billion in 2026.
• Business Quant data shows CELG-RI's Common Equity at $20.1 billion in Q1 2026, $18.5 billion in Q4 2025, and $18.6 billion in Q3 2025.